A detailed history of Natixis Advisors, L.P. transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Natixis Advisors, L.P. holds 10,042 shares of CRSP stock, worth $480,810. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,042
Previous 10,906 7.92%
Holding current value
$480,810
Previous $589,000 19.86%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

SELL
$44.62 - $62.75 $38,551 - $54,216
-864 Reduced 7.92%
10,042 $472,000
Q2 2024

Aug 01, 2024

BUY
$51.17 - $68.18 $20,468 - $27,272
400 Added 3.81%
10,906 $589,000
Q1 2024

Apr 25, 2024

BUY
$60.67 - $89.12 $22,144 - $32,528
365 Added 3.6%
10,506 $716,000
Q4 2023

Feb 06, 2024

SELL
$38.62 - $72.18 $60,478 - $113,033
-1,566 Reduced 13.38%
10,141 $634,000
Q3 2023

Nov 13, 2023

SELL
$45.39 - $59.0 $13,980 - $18,172
-308 Reduced 2.56%
11,707 $531,000
Q2 2023

Aug 15, 2023

SELL
$43.47 - $67.77 $18,865 - $29,412
-434 Reduced 3.49%
12,015 $675,000
Q1 2023

May 11, 2023

SELL
$41.0 - $56.12 $12,546 - $17,172
-306 Reduced 2.4%
12,449 $563,000
Q4 2022

Jan 27, 2023

SELL
$39.19 - $65.67 $105,891 - $177,440
-2,702 Reduced 17.48%
12,755 $519,000
Q3 2022

Nov 14, 2022

SELL
$61.1 - $83.78 $102,403 - $140,415
-1,676 Reduced 9.78%
15,457 $1.01 Million
Q2 2022

Aug 12, 2022

SELL
$43.23 - $73.83 $17,378 - $29,679
-402 Reduced 2.29%
17,133 $1.04 Million
Q1 2022

May 12, 2022

BUY
$53.19 - $79.24 $4,414 - $6,576
83 Added 0.48%
17,535 $1.1 Million
Q4 2021

Feb 08, 2022

SELL
$70.09 - $111.29 $117,470 - $186,522
-1,676 Reduced 8.76%
17,452 $1.32 Million
Q3 2021

Nov 15, 2021

BUY
$110.2 - $156.64 $1 Million - $1.43 Million
9,104 Added 90.82%
19,128 $2.14 Million
Q2 2021

Aug 12, 2021

BUY
$100.84 - $161.89 $1.01 Million - $1.62 Million
10,024 New
10,024 $1.62 Million

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.74B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Natixis Advisors, L.P. Portfolio

Follow Natixis Advisors, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Natixis Advisors, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Natixis Advisors, L.P. with notifications on news.